

F. No. CT/19/000004
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Global Clinical Trial Division)
FDA Bhawan, Kotla Road, New Delhi-110002
Te No: 01123236965, Fax: 01123236971
E-mail: dci@nic.in

To,

M/s. Kendle India Private Limited,
14th Floor Tower B, Building #14,
DLF Cyber City, Phase - III,
Gurgaon-122001, Haryana, (India).

Subject: Clinical trial titled “Xplore: A phase III, double-blind, parallel group, multicenter study to compare the efficacy and safety of Xlucane versus Lucentis® in patients with Neovascular age-related macular degeneration.”— regarding.

Reference: Your Application No. GCT/Form44/FF/2019/13123 (GCT/04/19) dated 22/Jan/2019.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the investigators mentioned below and as per the **Protocol No: XBR1001 Amendment 1, Version 2.0 dated 27/November/2018** submitted to this Directorate.

1. Dr. Aniruddha Maiti, Susrut Eye Foundation & Research Centre, Sector III, Salt Lake City, HB-36/A/1, Kolkata, West Bengal, India-700106.
2. Dr. Ramandeep Singh, Postgraduate Institute of Medical Education & Research (PGIMER), Sector 12, Chandigarh-160012, India.
3. Dr. Saroj Indersain Sahdev, Department of Ophthalmology, OPD No: 10, 2nd Floor, O.P.D. Building, T.N. Medical College and B.Y.L Nair Charitable Hospital, Dr. A.L. Nair Road, Mumbai-400008, Maharashtra, India.
4. Dr. Divya Balakrishnan, L V Prasad Eye Institute, Kallam Anji Reddy Campus, L.V Prasad Marg, Banjara Hills, Road No: 2, Hyderabad-500034, Telangana.
5. Dr. Manisha Agarwal, Dr. Shroff's Charity Eye Hospital, 5027, Kedarnath Road, Daryaganj, New Delhi-110002, India.
6. Dr. Chauhan Rohan Ramchandra, Rising Retina Clinic, 312-313, Iscon Center, Shivranjani Cross Roads, Satellite, Ahmedabad-380015, Gujarat, India.
7. Dr. Somesh Aggarwal, M & J Institute of Ophthalmology, Associated with B.J. Medical College & Civil Hospital, Asarwa, Ahmedabad-380016, Gujarat, India.
8. Dr. Tinku Bali Razdan, Sir Ganga Ram Hospital, Sir Ganga Ram Hospital Marg, Rajinder Nagar, New Delhi-110060, India.
9. Dr. Panchal Bhavik Uttam, L.V Prasad Eye Institute, GmrV Campus, Hanumanthwaka Junction, Visakhapatnam-530040, Andhra Pradesh, India.

10. Dr. Santosh Gopi Krishna. G, Narayana Nethralaya, 121/C, Chord Road, 1st R Block, Rajajinagar, Bangalore, Karnataka-560010.
11. Dr. Umesh Chandra Behera, L V Prasad Eye Institute, MTC Campus, Patia, Bhubaneswar-751024, Odisha, India.
12. Dr. Vishal Agrawal, Department of Ophthalmology, Charak Bhawan, SMS Hospital, JLN Marg, Jaipur-302004.
13. Dr. Pramod Kumar, King George's Medical University, Shahmeena Road, Chowk, Lucknow-226003.
14. Dr. Atul Hegade, PBMA's H.V. Desai Eye Hospital, S.No. 93, Tarawade Vasti, Mohmmadwadi Road, Hadapsar, Pune-411060.
15. Dr. Soumen Mondal, Disha Eye Hospitals Pvt. Ltd., 88 (63A) Ghosh Para Road, Barrackpore, Kolkata-700120, West Bengal, India.
16. Dr. Satish K, Department of Ophthalmology, K.R. Hospital, Mysore Medical College & Research Institute, Irwin Road, Mysore-570001, Karnataka, (India).
17. Dr. Perwez Khan, G.S.V.M Medical College, G.S. V. M Medical College, Swaroop Nagar, Kanpur (208002).
18. Dr. Santosh Shankar Bhide, Ruby Hall Clinic, 40, Sassoon Road, Pune-411001, Maharashtra, India.
19. Dr. Deepika Singhal, GMERS Medical College & Civil Hospital, Sola, Ahmedabad, Near Gujarat High Court, S.G. Highway, Ahmedabad, Gujarat, India, 380060.
20. Dr. Premnath Raman, JSS Hospital, Mahathma Gandhi Road, Mysuru-570004.
21. Dr. Kishore Tulsidas Pahuja, Natasha Eye Care & Research Centre, Building A Sai Saheb, Pimple Saudagar, Pune-411027.
22. Dr. Aratee Chandrashekar Palsule, LMMF's Deenanath Mangeshkar Hospital and Research Centre, Erandwane, Pune-411004, Maharashtra, India.
23. Dr. Prabhu Shanker Mahalingam, Sankara Eye Hospital, Sathy Road, Sivanandhapuram, Coimbatore-641035, Tamil Nadu, India.
24. Dr. Ajay Ambade, Ambade Eye Hospital, Kamptee Rd, Indora Chawk, Near Jaswant Inox, Nagpur-440017, Maharashtra, India.
25. Dr. Ezhil Vendhan, Vinayaka Mission's Kirupananda Variyar Medical College, Seeragapadi, Salem-636308, Tamil Nadu, India.
26. Dr. Sachin Daigavane, Acharya Vinoba Bhave Rural Hospital, A Constituent Unit of Datta Meghe Institute of Medical Science (Deemed University), Sawangi (M), Wardha (MS) 442004, Maharashtra, India.
27. Dr. Charmaine Bridgette Solomon, Govt. Medical College, Kozhikode, Kerala-673008.
28. Dr. D. Lionel Raj, Dr. Agarwal's Eye Hospital, No. 10, South bypass Road, Vannarpettai, Tirunelveli-627002, Tamilnadu.
29. Dr. Virendra Agarwal, Dr. Virendra Laser, Phaco Surgery Centre, Tonk Phatak, Behind Toyota Car Showroom, Tonk Road, Gandhi Nagar, Jaipur-302015.
30. Dr. Sudhir Kumar Garg, Maharaja Agrasen Hospital, West Punjabi Bagh, New Delhi-110026.
31. Dr. Alay Banker, Banker's Retina Clinic & Laser Centre, 5, Subhash Society, B/H Iswarbhuvan Society, Near H.L. Commerce College Six roads, Navarangpura, Ahmedabad-380009.

F. No. CT/04/19-DCG(I)

32. Dr. Smitha K S, KLES Dr. Prabhakar Kore Hospital and MRC, Nehru Nagar, Belagavi-590010, Karnataka, India.

33. Dr. Rahul Ashok Shroff, Shroff Eye Hospital & Vision Research Centre, 222, S.V. Road, Bandra West, Mumbai, Maharashtra, India 400050.

Note that the clinical trial permission is subject to the following conditions:

- a. Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
- b. Approval of the Ethics Committee shall be obtained before initiation of the study
- c. Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
- d. Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.
- e. Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.
- f. In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.
- g. The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.
- h. The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

F. No. CT/04/19-DCG(I)

- i. Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.
- j. The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.
- k. An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.
- l. It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.
- m. Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect as per the requirements specified in Appendix V of Schedule Y of the Drugs and Cosmetics Rules, 1945 must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

Yours faithfully,

**S ESWARA
REDDY**

Digitally signed by S ESWARA REDDY
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION,
2.5.4.20=cce9e6dd3ec4ca36d3ae9e432d59a6
f6c3a02bb467e76d5edcbb3a731ee144,
ou=CDGMS,CO=6432120,postalCode=110002,
st=Delhi, cn=S ESWARA REDDY
Date: 2019.05.02 14:33:17 +05'30'

**(Dr. S. Eswara Reddy)
Drugs Controller General (India)**